Skip to main content

Angiex Completes $3 million Seed Preferred Financing to Advance Its Vascular Approach to Cancer Therapy


CAMBRIDGE, MA. (July 28, 2017) – Angiex Inc. today announced that it has completed a $3 million seed preferred financing. The financing was led by Peter Thiel and included participation from Starling Ventures, WS Investments, and Wild Ventures.

The capital will enable Angiex to develop its innovative vascular-targeted antibody-drug conjugate therapy for solid tumors.

“Angiex is very pleased that Peter Thiel and other savvy biotech investors have invested in our innovative approach to cancer therapy,” said Paul Jaminet, Ph.D., Angiex’s founder and CEO. “With this capital, we expect to meet key product milestones and maintain our progress toward the clinic. We couldn’t be more excited to welcome these investors on board.”

“Angiex is developing a radically new approach to cancer therapy,” said Dr. Harold Dvorak, Angiex founder and Chief Medical Officer and Mallinckrodt Distinguished Professor of Pathology Emeritus at Harvard Medical School. “Angiex’s approach simultaneously targets both tumor cells and tumor vessels. This comprehensive approach offers potential for efficacy against the most dangerous solid tumors.”

About Angiex

Angiex was founded by world-class scientists to develop vascular-targeted biotherapeutics. Angiex targets fundamental aspects of endothelial biology with a focus on angiogenesis. Angiex’s lead product is an antibody-drug conjugate therapy for cancer. Angiex is resident at LabCentral in Cambridge, Massachusetts.